A temporary spike: Investigating Lennox–Gastaut syndrome incidence in the US following FDA approval of cannabidiol
Epileptic Disorders · 2026
DOI: 10.1002/epd2.70168 ↗Kurz gefasst
Fachartikel in der Zeitschrift Epileptic Disorders, 2026. Verfasst von Kaley J Marcinski Nascimento und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA. Hauptthemen laut MEDLINE: Lennox Gastaut Syndrome, Cannabidiol, Anticonvulsants. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Objective
In June 2018, the US Food and Drug Administration (FDA) approved pharmaceutical grade cannabidiol (CBD; Epidiolex®) for the treatment of seizures associated with Lennox–Gastaut syndrome (LGS). We sought to examine whether the FDA approval of CBD was associated with changes in LGS diagnostic practices in the United States.
Methods
We computed the annual number of new LGS diagnoses in the United States from 2017 to 2023 using a large, population‐based database of electronic health records.
Results
We identified a temporary increase in the number of new LGS diagnoses in 2019: the incidence rate rose by roughly 30% from 2018 to 2019, and almost 60% from 2017 to 2019, before it returned to pre‐FDA CBD approval baseline (2020–2023). Significance This temporary increase occurred in temporal proximity to the 2018 FDA approval of CBD for LGS. While causality cannot be inferred, this descriptive finding may reflect a confluence of factors including patient–caregiver interest and clinician practices to gain access to CBD. Clinician practices may have involved applying/updating LGS ICD codes to patients previously diagnosed with LGS and misdiagnosing patients with severe epilepsies as LGS. These findings underscore the clinical and research importance of appropriately using the LGS ICD code and ensuring accurate, reliable diagnosis of LGS based on standardized, well‐defined criteria. Nevertheless, given this work's reliance on administrative data, readers should interpret results cautiously, as misclassification and inconsistent coding practices can influence epidemiologic estimates and research conclusions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA.
- Department of Psychiatry, Virginia Tech Carilion School of Medicine, Roanoke, Virginia, USA.
- Department of Psychiatry and Behavioral Sciences, University of California San Francisco, San Francisco, California, USA.
- Lennox-Gastaut Syndrome Foundation, San Diego, California, USA.
- Jane and John Justin Institute for Mind Health, Cook Children's Medical Center, Fort Worth, Texas, USA.
- Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, USA.
ORCID-Profile: Kaley J Marcinski Nascimento, Fábio A Nascimento
Förderung
- NIDA NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Marcinski Nascimento, K. J., Li, Y., Lin, B. Y., Dixon-Salazar, T., Perry, M. S., Xu, K. Y., & Nascimento, F. A. (2026). A temporary spike: Investigating Lennox–Gastaut syndrome incidence in the US following FDA approval of cannabidiol. Epileptic Disorders. https://doi.org/10.1002/epd2.70168
Vancouver
Marcinski Nascimento KJ, Li Y, Lin BY, Dixon-Salazar T, Perry MS, Xu KY, et al. A temporary spike: Investigating Lennox–Gastaut syndrome incidence in the US following FDA approval of cannabidiol. Epileptic Disorders. 2026. doi:10.1002/epd2.70168
BibTeX
@article{MarcinskiNascimento2026,
author = {Marcinski Nascimento, Kaley J and Li, Yifan and Lin, Binx Y and Dixon-Salazar, Tracy and Perry, M Scott and Xu, Kevin Young and Nascimento, Fábio A},
title = {A temporary spike: Investigating Lennox–Gastaut syndrome incidence in the US following FDA approval of cannabidiol},
journal = {Epileptic Disorders},
year = {2026},
doi = {10.1002/epd2.70168}
}
EUVIMED